Our Signature Product
NOT ALL HYDROGELS ARE THE SAME
PAAG products, although often considered equal, have clear differences in composition, manufacturing and injection techniques as well as their ability to interact with surrounding tissues. These characteristics determine the safety and effectiveness of each hydrogel.
Arthramid Vet 2.5% PAAG
Arthramid Vet (AV) is a unique and patented hydrogel consisting of 97.5% sterile water and 2.5% polyacrylamide. This combination results in a gel similar to hyaluronic acid in structure and tissue compatibility, but with a superior and longer lasting effect, as it integrates into the joint itself and is non-degradable.
AV is elastic and viscous in nature, ideally suited for injection into the joints of animals providing an innovative and safe solution to veterinarians. Arthramid Vet is supplied in a sterile pre-filled 1ml syringe sealed with a Luer lock fitting.
AV is used to treat non-infectious causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA). OA can be caused by traumatic injury or usual wear and tear which causes the joint to become inflamed. As the cartilage or cushion between the joints breaks down, pain, stiffness, and swelling develop, causing lameness.
Lameness remains the most common cause of reduced performance in the equine industry. In addition to pain reduction, treatment should also serve to arrest or slow down the progression of lesions allowing for disease modification. It is now well recognised that the OA disease process can start with the disease in the synovial membrane and that inflamed synovium is an essential component in the pathogenesis, with it almost always being present in cases of OA.
As part of the OA complex, the elastic and viscous nature of the synovial fluid is abnormally low. Furthermore, the synovial membrane becomes a source of inflammatory products which contribute to the progressive degradation of the joint over time.
Studies have shown disease-modifying effects as Arthramid Vet integrates into the synovial membrane, stabilising the joint capsule, and increasing elasticity, which, in turn, reduces the onset of synovitis and its harmful effects. The formation of rejuvenated synovium improves the nature of the synovial fluid within the joint itself.
Additionally, Arthramid Vet essentially causes a ‘cushion-like’ effect in the joint which allows for the preservation and/ or regeneration of the joint cartilage contributing to reducing the pain of synovitis and OA, and ultimately restoring the joint function.
World Safety Standards
• Danish manufacturer Contura International A/S exceeds world-class safety standards
• Human & Vet quality production with a 15-year track record
• ISO 9001, ISO 13485 Canadian ISO 13485 CMDCAS
Arthramid Vet 2.5% PAAG
2.5% PAAG exerts its effect via integration over time within the joint capsule and adjacent soft tissues, through a combination of vessel in-growth, increased cell density, and molecular water exchange. de Clifford and Lowe, further assessed the composition and biocompatibility of 2.5% PAAG, by analysing pre and post-treatment synoviocentesis samples from 10 horses. There were no significant differences between treated and control joints and all values lie within normal laboratory reference limits in all horses up to 90 days post-treatment.
- Addresses Welfare Concerns
- Long-lasting Beneficial Effects on the Symptoms of OA
- Optimal Porosity For Tissue Integration
Get In Touch
32 Hill Road, Cambridge, NZ
Phone +64 (09) 8013 253
Innovative Medical Solutions
Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See www.foodsafety.govt.nz for registration conditions.